On February 27, 2025, the shares in Scandion Oncology A/S (the "Company") were given observation status with reference to information that the Company's board of directors would, if a partnership or financing solution was not secured by March 12, 2025, propose to the annual general meeting that the Company shall enter into voluntary liquidation.
On March 13, 2025, the observation status was updated with reference to the Company having disclosed its intention to enter into liquidation and delist its financial instruments from Nasdaq First North Growth Market.
Today, June 25, 2025, the Company issued a press release with information that the Company had submitted an application for delisting of its shares from Nasdaq First North Growth Market.
The rules of Nasdaq First North Growth Market state that a listed company can be given observation status if the issuer has applied to have the shares removed from trading.
With reference to the above, Nasdaq Stockholm AB decides to update the observation status for the shares in Scandion Oncology A/S (SCOL, ISIN code DK0061031895, order book ID 212648).
For further information about this exchange notice please contact Enforcement & Investigations, telephone +46 8 405 70 50.
